Praxis Precision Medicines, Inc (PRAX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $266.58: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 7.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Praxis is a clinical-stage CNS biopharmaceutical company developing precision therapies for neurological disorders via its Cerebrum (small molecule) and Solidus (ASO) platforms. It has submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A-DEE) based... Read more
Sell if holding. Engine safety override at $266.58: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 7.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Praxis Precision Medicines, Inc
Latest news
- NEWS Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650 — benzinga Jun 2, 2026 positive
- NEWS Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616 — benzinga Jun 2, 2026 positive
- NEWS Deutsche Bank Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $374 — benzinga Jun 2, 2026 positive
- NEWS Wedbush Maintains Underperform on Praxis Precision Medicine, Lowers Price Target to $162 — benzinga Jun 2, 2026 negative
- NEWS CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Jun 2, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineulixacaltamide10-K Item 1: 'Our most advanced program, ulixacaltamide, is a differentiated and highly selective small molecule inhibitor of T-type calcium channels'
Material Events(8-K, last 90d)
- 2026-02-10Item 5.02LOW8-K/A amending Jan 8, 2026 filing: Board appointed Jeffrey Kindler to Audit and Nominating Committees and Stuart Arbuckle to Compensation and Science & Technology Committees, effective February 6, 2026. Routine committee assignments for newly elected Class II directors.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $266.58: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 7.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $247.92. Score 5.4/10, moderate confidence.
Take-profit target: $564.83 (+111.9% upside). Prior stop was $247.92. Stop-loss: $247.92.
Concentration risk — Pipeline: ulixacaltamide; Quality below floor (1.6 < 4.0).
Praxis Precision Medicines, Inc trades at a P/E of N/A (forward -26.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover PRAX with a consensus score of 4.2/5. Average price target: $628.
What does Praxis Precision Medicines, Inc do?Praxis is a clinical-stage CNS biopharmaceutical company developing precision therapies for neurological disorders via...
Praxis is a clinical-stage CNS biopharmaceutical company developing precision therapies for neurological disorders via its Cerebrum (small molecule) and Solidus (ASO) platforms. It has submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A-DEE) based on positive Phase 3 data, with no approved products and no revenue yet.